Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte (DI) LSE:MXCT London Ordinary Share US57777K1060 COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 240.00p 235.00p 245.00p 240.00p 240.00p 240.00p 0 07:46:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 9.9 -2.7 -8.9 - 106.89

Maxcyte (DI) Share Discussion Threads

Showing 51 to 75 of 75 messages
Chat Pages: 3  2  1
DateSubjectAuthorDiscuss
22/9/2017
10:42
Short TV clip following this week's results: www.fmp-tv.co.uk/company/maxcyte-investor-videos-and-news/
oshy92
17/9/2017
13:36
Advances with CAR-T validate potential of CARMA platform The recent approval of Novartis’ CAR-T therapy, Kymriah, and the acquisition of Kite Pharma by Gilead for $12bn in cash provide further confirmation of the strong scientific and commercial rationale, respectively, of CAR-T therapies. It is worth noting that CARMA has the potential to address key challenges that currently face CAR-T therapies, including cost and safety issues. https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019 http://www.maxcyte.com/wp-content/uploads/2017/09/maxcyte-presentation_may-2017-updated1.pdf
davep4
07/6/2017
18:16
There is a new video on Proactiveinvestor where Doug Doerfler (CEO) discusses yesterday's news release concerning a possible treatment/cure for CGD http://www.proactiveinvestors.co.uk/companies/stocktube/7588/maxcyte-s-doug-doerfler-confident-of-providing-long-term-treatment-for-cgd-patients-7588.html http://www.investegate.co.uk/maxcyte--inc---mxct-/rns/research---development-agreement-with-niaid/201706060700052054H/ I confess I had never heard of CGD before today, but it is very, very rare (1 in 250,000), although the company has recently initiated another similar (NIH assisted) program using the same proprietary technology which could lead to a cure for Sickle Cell disease (which has a far greater incidence) https://en.wikipedia.org/wiki/Sickle-cell_disease
timbo003
03/4/2017
12:49
I believe the offer was substantially over subscribed Tim!
davep4
03/4/2017
07:16
I wasn't offered any this time around but would have passed anyway given the eventual placing price. It's quite unusual to get a big placing away at a premium, especially on AIM !
timbo003
31/3/2017
07:23
Good luck Tim!
davep4
31/3/2017
06:58
The proposed placing is for all the right reasons, I wonder what price they will get it away at and will any of it qualify for EIS? If I am given the opportunity to invest again I may have small nibble depending on the price and assuming the shares are issued in the next tax year and they qualify for EIS tax relief.
timbo003
28/3/2017
07:39
I think you could be right Tim, the question is at what price!
davep4
26/3/2017
12:24
Both Doug Doerfler (CEO) and Ron Holtz (CFO) were at the Proactive event on Thursday, unfortunately there was no hard copy of the slides to take away and there isn't a soft copy (yet) on the Proactive site, but I will request a copy and scribble a few notes tomorrow. I can see now why they are capitalised at >£100m and I really do not think they will be around as an independent company in 5 years time, somebody will take them out.
timbo003
16/3/2017
10:41
Maxcyte CEO Doug Doerfler will be presenting to investors at the upcoming Proactive One2One Forum taking place on the evening of 23rd March in Mayfair, London. For details and registration, please click here: https://tinyurl.com/zupvh3j
aim_trader
14/3/2017
18:18
I thought they might go a bit higher today on the back of that news, so I'll save the the next rocket for a better day, meanwhile there's a new interview with Doug Doerfler on Proactive investor which is well worth a listen: http://www.stocktube.com/video/7102/maxcyte-boss-doerfler-excited-by-gene-editing-licence-deal-7102.html in response to a question on why do they (i.e. big biotech) come to MaxCyte? DD states in his response: .......we can deliver any molecule to any cell at any scale and we do it highly efficiently, high performance and we also do it in a clinical setting so it can be used to modify those cells to engineer cells and return those cells to the patient and we are the only group who can do that clinically......" Which goes some way to explain why the shares are in such demand
timbo003
14/3/2017
08:41
Time for another Rocket video clip Tim?
davep4
14/3/2017
08:23
New Trinity Delta Research note now out following today's announcement: http://www.trinitydelta.org/notes-mxct
timbo003
10/3/2017
22:53
MaxCyte will be presenting at the Proactive investor evening on Thursday March 23rd, I plan to attend and will report back in due course: http://www.proactiveinvestors.co.uk/register/event_details/84
timbo003
13/2/2017
10:14
Mornin' ali I find it impossible to value this one, I bought primarily for the tax breaks as you know. I dont really believe in reading tea leaves, but I suspect the chartists would have said it was overdue a big correction at 280p, mind you they would probably have told you the same thing at 140p and 210p on the way up (and it didnt happen). This is one share where I havent been able to talk to the ,management, so all I have to go on is what is in the public domain. The Trinity Development research notes are a useful read if you haven't already seen them http://www.trinitydelta.org/notes-mxct
timbo003
12/2/2017
12:13
hi timbo you probably have studied this one thoroughly- i have been watching it and i notice it is down 30pc- but no clue as to whether this presents an opportunity to enter? just interested in your take!
ali47fish
07/2/2017
14:25
Let sleeping dogs lie timbo003!
davep4
06/2/2017
17:40
This is now a 4 bagger since the IPO, or a 5.5 bagger if you take into account the EIS tax relief. I find it quite extraordinary that there is no interest here. I would have thought at least the Scancell crowd might have had a sniff around, given that MaxCyte's business is all about Electroporation and Scancell's lead drug (SCIB1) requires electroporation for effective delivery.
timbo003
27/1/2017
16:35
Here's a date for your diaries 23rd March MaxCyte will be presenting at the Proactiveinvestor evening at the Chesterfield Hotel in Mayfair, It's free and you get fed and watered afterwards, so I've booked my place. http://www.proactiveinvestors.co.uk/register/event_details/84
timbo003
26/1/2017
17:29
Another good day, market cap now just a tad over £100m, presumably it will now get on a few more radar screens.
timbo003
25/1/2017
08:02
Thanks for that dave4p, there is also a new note available from Trinity Delta here: http://www.trinitydelta.org/notes-mxct
timbo003
24/1/2017
08:17
http://research.panmure.com/PGResearchDocuments/6733472.pgrd?subunit=221228
davep4
12/1/2017
08:21
The publication referred to in today's RNS appears to concern the work referred to in Panmure Gordon's morning note from last week. Up again today, now 3X the IPO price, or over 4X the price paid by IPO participants who qualified for EIS tax reliefs (i.e. 49p/share).
timbo003
11/1/2017
09:02
Yes and from memory 50+ licencees,(up from 30+ at the time of the float).
davep4
11/1/2017
08:38
Thanks Dave4p That note from Panmure puts the rise into context, so they are now looking at a new platform which is likely to be of considerable interest to big pharma and it sounds like Maxcyte are the only shop in town
timbo003
Chat Pages: 3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20171123 05:56:06